Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat

Pulmonary Circulation

Volumn 4, Issue 3, 2014, Pages 462-470

  Francis, Bahaa N ^a   Hale, Ashley ^b   Channon, Keith M ^b   Wilkins, Martin R ^a   Zhao, Lan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Endothelium; Nitric oxide; Pulmonary hypertension; Superoxide; Tetrahydrobiopterin

Indexed keywords

EID: 85026336629     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/677361     Document Type: Article

References (42)

1. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(1 suppl):S10–S19.
2. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443–455.
3. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 suppl):S3–S9.
4. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109(2): 159–165.
5. Alp NJ, Channon KM. Regulation of e ndothelial nitric oxidesynthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004;24(3):413–420.
6. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007;113(2):47–63.
7. Forstermann U. Oxidative stress in vascular disease: caus es,defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5(6):338–349.
8. Tsikas D, Bohmer A, Flentje M. Tetrahydrobiopterin and endothelial nitric oxide synthase uncoupling. Hypertension 2012;59(2):e12.
9. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25(1):29–38.
10. Jeremy JY, Yim AP, Wan S, Angelini GD. Oxidative stress, nitric oxide, and vascular disease. J Card Surg 2002;17(4): 324–327.
11. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005;115(5):1221–1231.
12. Khoo JP, Zhao L, Alp NJ, et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005;111(16):2126–2133.
13. Nandi M, Miller A, Stidwill R, et al. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation 2005;111(16):2086–2090.
14. Nandi M, Leiper J, Arrigoni F, Hislop A, Vallance P, Haworth S. Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation. Pediatr Res 2006;59(6):767–772.
15. Francis BN, Wilkins MR, Zhao L. Tetrahydrobiopterin (BH4) and the regulation of hypoxic pulmonary vasoconstriction. Eur Respir J 2010;36:323–330.
16. Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med 2006;41(12):1764–1770.
17. Zhao L, Sebkhi A, Ali O, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009;34(4):948–957.
18. Cosentino F, Hurlimann D, Delli GC, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 2008;94(4):487–492.
19. Giraldez RR, Zweier JL. An improved assay for measurement of nitric oxide synthase activity in biological tissues. Anal Biochem 1998;261(1):29–35.
20. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007;49(4):717–727.
21. Wilkins MR. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev 2012;21(123):19–26.
22. Turanlahti M, Pesonen E, Pohjavuori M, Lassus P, Fyhrquist F, Andersson S. Plasma cyclic guanosine monophosphate reflecting the severity of persistent pulmonary hypertension of the newborn. Biol Neonate 2001;80(2):107–112.
23. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995;73(1):65–68.
24. Tessler R, Wu S, Fiori R, Macgowan CK, Belik J. Sildenafil acutely reverses the hypoxic pulmonary vasoconstriction response of the newborn pig. Pediatr Res 2008;64(3):251–255.
25. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104(4):424–428.
26. Zhao L. Chronic hypoxia-induced pulmonary hypertension in rat: the best animal model for studying pulmonary vasoconstriction and vascular medial hypertrophy. Drug Discov Today Dis Models 2010;7:83–88.
27. Le Cras TD, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol Lung Cell Mol Physiol 1996;270(1):L164–L170.
28. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 1997; 272(22):H806–H813.
29. Tyler RC, Muramatsu M, Abman SH, et al. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 1999;276(2):L297–L303.
30. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 2002;277(46):44085–44092.
31. Cracowski JL, Cracowski C, Bessard G, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001;164(6):1038–1042.
32. Robbins IM, Morrow JD, Christman BW. Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med 2005;38(5):568–574.
33. Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169(6):764–769.
34. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitricoxide synthase. J Biol Chem 2003;278(25):22546–22554.
35. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111(8): 1201–1209.
36. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circ 2001;103(9):1282–1288.
37. Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001;90(4): 1299–1306.
38. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 2006;290(1):L2–L10.
39. Wu W, Platoshyn O, Firth AL, Yuan JX. Hypoxia divergently regulates production of reactive oxygen species in human pulmonary and coronary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2007;293(4):L952–L959.
40. Cunnington C, Van AT, Shirodaria C, et al. Systemic and vascular oxidation limits efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012;125:1356–1366.
41. Kunuthur SP, Milliken PH, Gibson CL, Suckling CJ, Wadsworth RM. Tetrahydrobiopterin analogues with NOdependent pulmonary vasodilator properties. Eur J Pharmacol 2011;650(1):371–377.
42. Robbins IM, Hemnes AR, Simon GJ, et al. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res 2011;37(1):26–34.